ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO300

Association Between Use of Proton Pump Inhibitors and Hypomagnesemia: A Meta-Analysis

Session Information

Category: Fluid and Electrolytes

  • 902 Fluid and Electrolytes: Clinical


  • Susantitaphong, Paweena, Chulalongkorn University, Bangkok, Thailand
  • Srinutta, Thawin, Chulalongkorn University, Bangkok, Thailand
  • Chewcharat, Api, Chulalongkorn University, Bangkok, Thailand
  • Takkavatakarn, Kullaya, Division of Nephrology, King Chulalongkorn Memorial hospital, Bangkok, Thailand
  • Praditpornsilpa, Kearkiat, Chulalongkorn University, Bangkok, Thailand
  • Jaber, Bertrand L., St. Elizabeth's Medical Center, Boston, Massachusetts, United States
  • Eiam-Ong, Somchai, Chulalongkorn University, Bangkok, Thailand

Hypomagnesemia is associated with an increased risk of cardiac arrhythmia and mortality. The use of proton pump inhibitors (PPIs) has been inconsistently associated with development of hypomagnesemia. To shed more light on this controversy, we performed a meta-analysis to examine the association between use of PPIs and hypomagnesemia.


The literature search was conducted in MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials (through December 2017) to identify observational studies that examined the association between use of PPIs and development of hypomagnesemia. Random-effects model meta-analysis was used to compute the pooled odds ratio (OR) with 95% confidence interval (CI).


Thirteen cohort studies were identified, totaling 125,280 patients. 38.7% (95% CI 29.5-48.7%) of patients were PPI users. The baseline prevalence of diabetes mellitus and diuretic use was not significantly different between PPI users and non-users. By meta-analysis, use of PPIs was associated with a higher odds for development of hypomagnesemia (pooled odds ratio 1.83; 95% CI 1.26, 2.67; P = 0.002; I2 = 97%).


The use of PPIs is significantly associated with development of hypomagnesemia. As a result, serum magnesium levels should be monitored in patients receiving long-term PPIs.